中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2011年
1期
56-58
,共3页
侯旭%赵岩%郑永日%王建交%武志超%孙家行
侯旭%趙巖%鄭永日%王建交%武誌超%孫傢行
후욱%조암%정영일%왕건교%무지초%손가행
胶质瘤%O(6)-甲基鸟嘌呤DNA转移酶%核苷酸切除修复交叉互补基因2%替莫唑胺
膠質瘤%O(6)-甲基鳥嘌呤DNA轉移酶%覈苷痠切除脩複交扠互補基因2%替莫唑胺
효질류%O(6)-갑기조표령DNA전이매%핵감산절제수복교차호보기인2%체막서알
Glioma%MGMT protein%ERCC2 protein%Temozolomide
目的 研究人脑胶质瘤组织中两种耐药基因MGMT、ERCC2对于替莫唑胺治疗恶性胶质瘤产生耐药性的影响及两种耐药基因表达上的相关关系.方法 将58例应用替莫唑胺化疗的恶性胶质瘤患者经随诊分为治疗敏感组和不敏感组,58例患者年龄为19～68岁,其中治疗敏感组28例,治疗不敏感组30例.利用免疫组化的方法分析MGMT、ERCC2的表达率,用免疫组化以及RT-PCR的方法分析两种基因表达相关性.结果 在替莫唑胺治疗敏感组中MGMT、ERCC2阳性表达率分别为10.71%、3.57%,不敏感组中MGMT、ERCC2阳性表达率分别为63.33%、56.67%;并且MGMT、ERCC2的表达经免疫组化和RT-PCR方法分析均具有明显相关性(均P＜0.01).结论 MGMT、ERCC2基因表达在替莫唑胺治疗敏感患者的表达率明显低于治疗不敏感患者表达率,两种基因的表达对肿瘤的预后可能相关,且两种基因表达之间具有一定的相关性,可能共同参与细胞DNA损伤的修复,形成肿瘤耐药.
目的 研究人腦膠質瘤組織中兩種耐藥基因MGMT、ERCC2對于替莫唑胺治療噁性膠質瘤產生耐藥性的影響及兩種耐藥基因錶達上的相關關繫.方法 將58例應用替莫唑胺化療的噁性膠質瘤患者經隨診分為治療敏感組和不敏感組,58例患者年齡為19～68歲,其中治療敏感組28例,治療不敏感組30例.利用免疫組化的方法分析MGMT、ERCC2的錶達率,用免疫組化以及RT-PCR的方法分析兩種基因錶達相關性.結果 在替莫唑胺治療敏感組中MGMT、ERCC2暘性錶達率分彆為10.71%、3.57%,不敏感組中MGMT、ERCC2暘性錶達率分彆為63.33%、56.67%;併且MGMT、ERCC2的錶達經免疫組化和RT-PCR方法分析均具有明顯相關性(均P＜0.01).結論 MGMT、ERCC2基因錶達在替莫唑胺治療敏感患者的錶達率明顯低于治療不敏感患者錶達率,兩種基因的錶達對腫瘤的預後可能相關,且兩種基因錶達之間具有一定的相關性,可能共同參與細胞DNA損傷的脩複,形成腫瘤耐藥.
목적 연구인뇌효질류조직중량충내약기인MGMT、ERCC2대우체막서알치료악성효질류산생내약성적영향급량충내약기인표체상적상관관계.방법 장58례응용체막서알화료적악성효질류환자경수진분위치료민감조화불민감조,58례환자년령위19～68세,기중치료민감조28례,치료불민감조30례.이용면역조화적방법분석MGMT、ERCC2적표체솔,용면역조화이급RT-PCR적방법분석량충기인표체상관성.결과 재체막서알치료민감조중MGMT、ERCC2양성표체솔분별위10.71%、3.57%,불민감조중MGMT、ERCC2양성표체솔분별위63.33%、56.67%;병차MGMT、ERCC2적표체경면역조화화RT-PCR방법분석균구유명현상관성(균P＜0.01).결론 MGMT、ERCC2기인표체재체막서알치료민감환자적표체솔명현저우치료불민감환자표체솔,량충기인적표체대종류적예후가능상관,차량충기인표체지간구유일정적상관성,가능공동삼여세포DNA손상적수복,형성종류내약.
Objective To study the impact of two human glioma tissue resistance genes MGMT and ERCC2 on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions. Methods A total of 58 malignant glioma patients aged 19 -68 years old receiving a chemotherapy of temozolomide were followed up and classified as non-sensitive group (n = 30) and sensitive group (n = 28). Immunohistochemistry was employed to detect the expression rates of MGMT and ERCC2.And the correlation between the expressions of two genes was analyzed by immunohistochemistry and RT-PCR (reverse transcription-polymerase chain reaction). Results The expression rates of MGMT and ERCC2were 10. 71% and 3.57% in the sensitive group and 63.33% and 56. 67% in the non-sensitive group. It had an obvious correlation with the expressions of MEGT and ERCC2 through an analysis of immunohistochemistry and RT-PCR (both P ＜0. 01 ). Conclusion The expressions of MGMT and ERCC2in the sensitive group are markedly lower than those in the non-sensitive group. The expression of two genes may be related to tumor prognosis. Maybe these two genes have an intrinsic link between their expressions.Both participate in the repair of cellular DNA damage and the formation of tumor drug resistance. And the prognosis has obvious relevance.
